Evonik Archives - Medical Design Sourcing

Evonik enters agreement to produce silk proteins for AMSilk

Evonik announced today that it entered into an agreement with AMSilk to produce sustainable silk proteins.

AMSilk, a Germany-based biotech company, develops innovative, sustainable silk proteins. The uses of the silk include a broad range of applications including medical devices. They provide optimal performance and minimal environmental impact, according to a news release.

Essen, Germany-based Evonik’s agreement covers the production of industrial quantities of the silk proteins. Evonik plans to produce the silk at its contract development and manufacturing (CDMO) precision fermentation site in Slovakia.

“Working with a partner who puts sustainability at the heart of their business is in perfect alignment with our goals at Evonik. We are delighted to partner with AMSilk to bring smart biotech silk materials to industries worldwide,” said Thomas Riermeier, head of the Health Care business line at Evonik.

AMSilk turns man-made proteins into …

Evonik, Coopmed agree on wound dressing distro deal

Evonik announced today that it signed an agreement for medical technology company Coopmed to distribute the epicite wound dressing.

Jena, Germany-based Evonik said Coopmed will distribute the epicite dressing made from biosynthetic cellulose exclusively to the German market for chronic wound care. Epicite represents part of the portfolio from JeNaCell, which Evonik acquired in 2021.

“We are excited to work with a highly experienced partner like Coopmed for the market development and distribution of epicite® to advance the treatment of chronic wounds,” said Dana Kralisch, GM of JeNaCell. “Together, we will work to make epicite® available to outpatients throughout Germany. We would like to thank all wound experts and professional users who supported us with case studies, practical advice and their personal experiences using the product.”

JeNaCell is designed to produce biosynthetic cellulose. The nature-identical material is suitable for wound cleansing an…

Evonik launches new Eudratec tech to boost solubility of oral small molecules

Evonik (Essen, Germany) announced today that it now offers Eudratec SoluFlow, a microparticle technology meant to enhance solubility of active pharmaceutical ingredients in oral drug products.

The emulsion-based process technology overcomes solubility hurdles that cannot be resolved by existing manufacturing technologies, according to Evonik.

With more than 70% of new small molecules being insoluble, Eudratec SoluFlow could enable the development of oral therapeutics in areas such as cancer, cardiovascular diseases, infectious diseases, and diabetes, according to Evonik.

“Our new technology opens doors to a wider spectrum of oral drugs by enabling the use of molecules that were previously considered insoluble. We look forward to working with customers to develop oral drugs for better, healthier lives,” said Paul Spencer, head of Drug Delivery & Medical Device Solutions at Evonik’s Health Care business.

The emulsion-based process uses standard …

Evonik launches new Eudratec tech to boost solubility of oral small molecules

Evonik (Essen, Germany) announced today that it now offers Eudratec SoluFlow, a microparticle technology meant to enhance solubility of active pharmaceutical ingredients in oral drug products.

The emulsion-based process technology overcomes solubility hurdles that cannot be resolved by existing manufacturing technologies, according to Evonik.

With more than 70% of new small molecules being insoluble, Eudratec SoluFlow could enable the development of oral therapeutics in areas such as cancer, cardiovascular diseases, infectious diseases, and diabetes, according to Evonik.

“Our new technology opens doors to a wider spectrum of oral drugs by enabling the use of molecules that were previously considered insoluble. We look forward to working with customers to develop oral drugs for better, healthier lives,” said Paul Spencer, head of Drug Delivery & Medical Device Solutions at Evonik’s Health Care business.

The emulsion-based process uses standard …

Evonik invests in Revivo BioSystems and its compound-testing technology

Evonik announced that it invested in startup Revivo BioSystems to support the development and commercialization of its technology.

Essen, Germany-based Evonik said in a news release that Revivo BioSystems develops technology that uses a realistic 4D model of human skin to test chemical, cosmetic and pharmaceutical compounds, offering an alternative to animal testing that can be quicker, more reliable and more cost-efficient.

Singapore-based Revivo’s organ-on-a-chip technology automates testing and sampling procedures in addition to simulating the interaction of human skin with the substance being tested. Skin tissues grown in a laboratory (or a human skin sample) are placed on biochips that are supplied with nutrients and reagents, creating a micro-environment for the tissue models, which reproduce the architecture and functions of skin.

Evonik said consumers prefer substances that haven’t been tested on animals, while more than 40 countries …

Evonik launches new Resomer PrintPowder polymers for 3D printing of personalized, implantable medical devices

Evonik’s Resome PrintPowder is used for 3D printing medical devices and implants. [Photo courtesy of Evonik]

Evonik has launched the second generation of Resomer PrintPowder polymers for 3D printing of personalized, implantable medical devices.

Essen, Germany-based Evokik said the powders have a broader range of customizable mechanical properties and degradation rates, allowing their use for more complex and tailored medical devices including orthopedic, dental, or soft tissue applications.

“These new powders will allow manufacturers to create personalized devices with complex internal designs that match a patient’s anatomy — this will open up new treatment options for patients,” Thomas Riermeier, head of Evonik’s Health Care business line, said in a news release.

Evonik also offers comprehensive selective laser sintering (SLS) application and printing service support for the new powde…

Evonik acquires JeNaCell and its nanostructured biomaterial

Evonik (Essen, Germany) recently announced that has purchased JeNaCell and its nanostructured biomaterial for wound dressings and dermatology.

The financial terms of the deal were not disclosed.

JeNaCell (Jena, Germany) provides biotechnologically derived cellulose. Evonik first invested in the startup in 2015.

“JeNaCell has developed one of the most innovative biomaterials for medical device technologies. With the help of the creativity and expertise of JeNaCell’s specialists, we will ensure that even more patients benefit from these products in the future,” said Thomas Riermeier, head of Evonik’s Health Care business line, said in an Aug. 2 news release. “The acquisition will help us to further strengthen our position as an innovation hub for the world’s leading medical technology companies.”

How silica can support cold chain logistics

Aerosil-based vacuum insulation panels feature multiple layers of a special film for ideal insulation against hot and cold temperatures.

In the early days of the pandemic, the subarctic storage requirements for mRNA COVID-19 vaccines sparked renewed interest in the cold chain. One potentially overlooked element of the cold chain is silica, according to the specialty chemicals company Evonik. The company states that its Aerosil fumed silica supports passively cold transport units using cool packs or dry ice. Specifically, fumed silica supports passive cooling without an external energy source. The company synthesizes its vacuum insulation panels (VIPs) lined with Aerosil in a 1200° C hydrogen flame. VIPs filled with fumed silica offer substantial insulation with a thin layer of material. Fumed silica–based materials are thus suitable for use in insulating containers or boxes for temperature-controlled transport of g…